ReviewArchives of microbiology2026
IgY technology (egg yolk antibodies) in respiratory medicine: applications and future prospects.
Review in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The respiratory system is under strain due to rising infections and diseases affecting millions globally, with antimicrobial resistance, allergens, and the recent pandemic further burdening public health. These challenges emphasize the critical need for support-based adjunct or combination biologics as essential measures for combating disease pathogenesis and optimizing the rational use of antimicrobials and steroids. Passive immunization represents an encouraging approach, with immunoglobulin Y (IgY) derived from hyperimmunized hen egg yolk emerging as a promising, cost-effective, and ethical alternative to conventional mammalian-derived antibodies. IgY technology addresses challenges including stability, process complexity, and antimicrobial resistance, offering practical advantages for human and animal applications. This review examines the application of IgY technology against majorly evolving respiratory pathogens and conditions - influenza virus, SARS-CoV-2, respiratory syncytial virus, Mycobacterium tuberculosis, Streptococcus pneumoniae, and respiratory allergens - highlighting IgY technology's significance as biologics across viral, bacterial, and allergen-driven respiratory diseases. Evidence from the IgY literature is broadly encouraging, demonstrating efficacy in pathogen neutralization, virulence attenuation, and hypersensitivity suppression, particularly through intranasal and oral delivery routes. IgY technology represents an affordable and scalable tool for low- and middle-income countries (LMICs) and beyond. Future priorities should include standardized antibody production protocols, optimized formulations and dosing strategies, rational point-of-care diagnostic integration, and well-designed prospective trials in high-burden settings to bring forth IgY technology's translational potential against prevailing and forthcoming respiratory afflictions.
Indexed as
Identifiers
42262426What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.